EPO and tauopathy: Chronic dosing of the BBB-penetrating cTfRMAb-EPO fusion protein reversed altered anxiety and hyperactive phenotypes and reduced phosphorylated tau and microgliosis, demonstrating therapeutic effects in a PS19 transgenic mouse model of tauopathy.